Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INCY 
Incyte Corporation (INCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: INCY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
27 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $75.15
1 Year Target Price $75.15
| 8 | Strong Buy |
| 3 | Buy |
| 15 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.46% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.23B USD | Price to earnings Ratio 341.85 | 1Y Target Price 75.15 |
Price to earnings Ratio 341.85 | 1Y Target Price 75.15 | ||
Volume (30-day avg) 27 | Beta 0.68 | 52 Weeks Range 53.56 - 83.95 | Updated Date 06/30/2025 |
52 Weeks Range 53.56 - 83.95 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.48% | Operating Margin (TTM) 20.65% |
Management Effectiveness
Return on Assets (TTM) 2.04% | Return on Equity (TTM) 0.47% |
Valuation
Trailing PE 341.85 | Forward PE 11.75 | Enterprise Value 10872708786 | Price to Sales(TTM) 3 |
Enterprise Value 10872708786 | Price to Sales(TTM) 3 | ||
Enterprise Value to Revenue 2.46 | Enterprise Value to EBITDA 26.73 | Shares Outstanding 193570000 | Shares Floating 161065671 |
Shares Outstanding 193570000 | Shares Floating 161065671 | ||
Percent Insiders 2.22 | Percent Institutions 100.64 |
Analyst Ratings
Rating 5 | Target Price 75.15 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold 15 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Incyte Corporation
Company Overview
History and Background
Incyte Corporation, founded in 2002, is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines to meet unmet medical needs, primarily in oncology and hematology. It evolved from a genomics company to a drug development firm.
Core Business Areas
- Oncology: Incyte focuses on developing and commercializing treatments for various cancers, including hematologic malignancies and solid tumors.
- Inflammation and Autoimmunity: Incyte develops therapies for inflammatory and autoimmune diseases, like atopic dermatitis and vitiligo.
Leadership and Structure
Herve Hoppenot is the CEO. The company has a typical corporate structure with a board of directors and various functional departments including R&D, commercial, and operations.
Top Products and Market Share
Key Offerings
- Jakafi (ruxolitinib): Jakafi is a JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It generates significant revenue for Incyte. Competitors include generics and other therapies like momelotinib. Market share is substantial in its approved indications, varying by specific disease area. In Q1 2024, Jakafi net product revenue was $674 million.
- Opzelura (ruxolitinib cream): Opzelura is a topical formulation of ruxolitinib approved for atopic dermatitis and vitiligo. It is growing in the dermatology space. Competitors include topical corticosteroids and other emerging therapies. Market share is increasing in the atopic dermatitis and vitiligo markets. Net product revenue in Q1 2024 was $98 million.
- Pemazyre (pemigatinib): Pemazyre is a selective FGFR2 inhibitor approved for cholangiocarcinoma. Competitors include other chemotherapy regimens and emerging targeted therapies. Market share is niche, focused on FGFR2-fusion positive cholangiocarcinoma. Q1 2024 net product revenue was $24 million.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. It is highly competitive with a mix of large pharmaceutical companies and smaller biotechnology firms.
Positioning
Incyte is positioned as a mid-sized biopharmaceutical company with a strong focus on hematology, oncology, and dermatology. It has a competitive advantage in JAK inhibition and targeted therapies.
Total Addressable Market (TAM)
The TAM for Incyte's target markets (oncology, hematology, dermatology) is very large, estimated in the hundreds of billions of dollars. Incyte is positioned to capture a significant share through its innovative therapies. Opzelura for dermatology has a sizable TAM due to large number of potential patients.
Upturn SWOT Analysis
Strengths
- Approved and marketed products (Jakafi, Opzelura, Pemazyre)
- Strong R&D pipeline
- Expertise in JAK inhibition
- Strategic partnerships
- Experienced management team
Weaknesses
- Reliance on Jakafi revenue
- High R&D expenses
- Competition from larger pharmaceutical companies
- Regulatory risks
- Potential for generic erosion of Jakafi
Opportunities
- Expanding indications for existing products
- Developing novel therapies for unmet needs
- Strategic acquisitions and collaborations
- Geographic expansion
- Pipeline advancements
Threats
- Generic competition for Jakafi
- Clinical trial failures
- Regulatory setbacks
- Pricing pressures
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- VRTX
- GILD
- MRK
Competitive Landscape
Incyte competes with larger pharmaceutical companies and specialized biotechnology firms. Its competitive advantage lies in its targeted therapies and expertise in specific disease areas.
Major Acquisitions
Villaris Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 143
- Strategic Rationale: This acquisition brought the anti-IL-15 antibody program, now known as Vidilitumab, into Incyte's pipeline for the treatment of vitiligo.
Growth Trajectory and Initiatives
Historical Growth: Incyte has experienced significant growth driven by the success of Jakafi and the launch of new products like Opzelura.
Future Projections: Analysts project continued revenue growth driven by existing products and pipeline advancements. Earnings are also expected to increase.
Recent Initiatives: Recent initiatives include expanding indications for Opzelura, advancing pipeline programs, and pursuing strategic collaborations.
Summary
Incyte is a biopharmaceutical company with a strong focus on oncology, hematology, and dermatology. Its revenue is largely driven by Jakafi, and Opzelura showing future potential. While its R&D pipeline is promising, dependence on one drug and potential generic erosion pose risks. Strategic collaborations and pipeline advancements are key to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Incyte Corporation SEC Filings
- Company Investor Relations
- Analyst Reports
- Various financial websites
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incyte Corporation
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 1993-11-04 | Chairman, President & CEO Mr. Herve Hoppenot | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2617 | Website https://www.incyte.com |
Full time employees 2617 | Website https://www.incyte.com | ||
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.